<DOC>
	<DOCNO>NCT01552343</DOCNO>
	<brief_summary>The purpose study assess psychometric property ( reliability validity ) Nocturia Impact ( NI ) diary . To assess association reduction number nocturnal void mean change NI score ( sensitivity NI total score change nocturia ) . To assess NI diary item account main difference change total NI score treatment versus placebo .</brief_summary>
	<brief_title>Study Investigating Impact Burden Nocturia Using Nocturia Impact Diary</brief_title>
	<detailed_description />
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>1 . Written inform consent prior performance studyrelated activity 2 . 18 year age ( time write consent ) old 3 . Previous participation FE992026 CS40 FE992026 CS41 completion ≥ 30 day prior Screening . The subject respond active treatment FE992026 CS40 FE992026 CS41 he/she receive placebo two study he/she nonresponder . 4 . At least two nocturnal void every night two consecutive 3day period screen period ( determine two nighttime void diary dispense Visit 1 collect Visit 2 ) 1 . Chronic prostatitis ( male ) /chronic pelvic pain syndrome ( CPPS ) 2 . Suspicion bladder outlet obstruction ( BOO ) urine flow &lt; 5 mL/s confirm uroflowmetry perform suspicion BOO 3 . Surgical treatment , include transurethral resection , BOO benign prostatic hyperplasia ( male ) within past six month 4 . Urinary retention post void residual volume &gt; 150 mL female &gt; 250 mL male confirm bladder ultrasound perform suspicion urinary retention 5 . Central nephrogenic diabetes insipidus 6 . Syndrome inappropriate antidiuretic hormone 7 . Current history urologic malignancy e.g . bladder cancer 8 . Genitourinary tract pathology e.g . infection stone bladder urethra cause symptom 9 . Neurogenic detrusor activity ( detrusor overactivity ) 10 . Suspicion evidence cardiac failure 11 . Chronic prostatitis ( male ) /chronic pelvic pain syndrome ( CPPS ) 12 . Uncontrolled hypertension 13 . Uncontrolled diabetes mellitus 14 . Hyponatraemia : serum sodium level must within normal limit 15 . Renal insufficiency : Serum creatinine must within normal limit estimate glomerular filtration rate must ≥ 50 mL/min 16 . Hepatic and/or biliary disease : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) level must twice upper limit normal range . Total bilirubin level must &gt; 1.5 mg/dL 17 . History obstructive sleep apnea 18 . Treatment another investigational product ( except desmopressin ) within three month prior screen throughout study 19 . Concomitant treatment loop diuretic ( furosemide , torsemide , ethacrynic acid ) 20 . Pregnancy , breastfeeding , intention become pregnant period clinical study . Female subject reproductive age must documentation reliable method contraception . All preand perimenopausal female subject perform pregnancy test . Amenorrhea &gt; 12 month duration base report date last menstrual period sufficient documentation postmenopausal status require pregnancy test 21 . Known alcohol substance abuse 22 . Work lifestyle may interfere regular nighttime sleep e.g . shiftworkers 23 . Any medical condition , laboratory abnormality , psychiatric condition , mental incapacity , language barrier , judgment Investigator , would impair participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>